Comment from Pharmaceutical Research and Manufacturers of America (PhRMA)

Summary: PhRMA, representing leading biopharmaceutical companies, supports the FDA's draft guidance on genome editing safety assessments. They advocate for a risk-based, "fit-for-purpose" regulatory framework that provides more clarity on analytical thresholds, off-target site filtering, and specific requirements for different editing modalities to ensure regulatory predictability and innovation.